Andrea Lobo, PhD, science writer —

Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, including stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.

Articles by Andrea Lobo

Health Canada now reviewing Qalsody as treatment for SOD1-ALS

Health Canada is now reviewing Qalsody (tofersen) as a potential treatment for people with amyotrophic lateral sclerosis (ALS) who carry mutations in the SOD1 gene, according to the therapy’s developer Biogen. The Canadian regulatory authority agreed to review Biogen’s application for the therapy’s approval, with its decision expected in early 2025, according to…

Coave wins grant to advance gene therapy CTx-TFEB for ALS

Coave Therapeutics has received a grant from the ALS Association to support the development of its gene therapy candidate CTx-TFEB for amyotrophic lateral sclerosis (ALS). The grant, made through the Lawrence and Isabel Barnett Drug Development Program, is part of the $2.9 million the ALS Association…

OrphAI’s AIT-101 granted orphan drug status in Europe for ALS

OrphAI Therapeutics’ experimental therapy AIT-101 has been awarded orphan drug status in the European Union for amyotrophic lateral sclerosis (ALS), following a similar designation granted in the U.S. last year. In Europe, orphan drug status is given to medicines designed to treat life-threatening or chronically debilitating conditions affecting…

Committee favors EU approval of Qalsody for adults with SOD1-ALS

An advisory committee of the European Medicines Agency (EMA) has recommended that Biogen’s Qalsody (tofersen) be approved in the European Union under exceptional circumstances to treat adults with amyotrophic lateral sclerosis (ALS) associated with SOD1 gene mutations. The positive opinion from the Committee for Medicinal Products for Human Use,…